It is well known that (1) different genetic mutations in EGFR gene are described in a high percentage of NSCLC patients worldwide45, and (2) EGFR constitutive activation is required for lung adenocarcinoma progression25. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.